{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:29Z","timestamp":1787021249874,"version":"build-2736575974"},"reference-count":92,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"DOI":"10.1210\/jc.2003-030518","type":"journal-article","created":{"date-parts":[[2003,10,13]],"date-time":"2003-10-13T13:42:51Z","timestamp":1066052571000},"page":"4759-4767","source":"Crossref","is-referenced-by-count":59,"title":["Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm"],"prefix":"10.1210","volume":"88","author":[{"given":"David R.","family":"Clemmons","sequence":"first","affiliation":[{"name":"University of North Carolina at Chapel Hill (D.R.C.), Chapel Hill, North Carolina 27599;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Chihara","sequence":"additional","affiliation":[{"name":"Division of Endocrinology\/Metabolism, Neurology, and Hematology\/Oncology (K.C.), Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Hyogo 650-0017, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela U.","family":"Freda","sequence":"additional","affiliation":[{"name":"Department of Medicine (P.U.F.), Columbia University College of Physicians and Surgeons, New York, New York 10032;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken K. Y.","family":"Ho","sequence":"additional","affiliation":[{"name":"Pituitary Research Unit (K.K.Y.H.), Garvan Institute of Medical Research, and Department of Endocrinology, St. Vincent\u2019s Hospital, Darlinghurst 2010, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Klibanski","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit (A.K.), Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[{"name":"Cedars Sinai Medical Center (S.M.), University of California School of Medicine, Los Angeles, California 90048;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Shalet","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (S.M.S., P.J.T.), Christie Hospital, Manchester M20-4BX, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (C.J.S.), Department of Medicine, Charite Campus Mitte, D-80336 Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Trainer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (S.M.S., P.J.T.), Christie Hospital, Manchester M20-4BX, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Thorner","sequence":"additional","affiliation":[{"name":"Department of Medicine (M.O.T.), University of Virginia Health System, Charlottesville, Virginia 22908"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2019041117351758200_R1","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jcem.83.10.5111","article-title":"Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results.","volume":"83","author":"Abosch","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","article-title":"Epidemiology of acromegaly in the Newcastle region.","volume":"12","author":"Alexander","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"2019041117351758200_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0026-0495(95)90303-8","article-title":"Does treatment of acromegaly affect life expectancy","volume":"44","author":"Bates","year":"1995","journal-title":"Metabolism"},{"key":"2019041117351758200_R4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1009965803750","article-title":"Epidemiology of acromegaly.","volume":"2","author":"Holdaway","year":"1999","journal-title":"Pituitary"},{"key":"2019041117351758200_R5","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.","volume":"83","author":"Orme","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2265.1994.tb03789.x","article-title":"Determinants of clinical outcome and survival in acromegaly.","volume":"41","author":"Rajasoorya","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R7","first-page":"1","article-title":"Mortality in acromegaly.","volume":"39","author":"Wright","year":"1970","journal-title":"Q J Med"},{"key":"2019041117351758200_R8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","article-title":"Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.","volume":"223","author":"Bengtsson","year":"1988","journal-title":"Acta Med Scand"},{"key":"2019041117351758200_R9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","article-title":"Acromegaly.","volume":"26","author":"Nabarro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R10","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1172\/JCI112742","article-title":"Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma.","volume":"78","author":"Baxter","year":"1986","journal-title":"J Clin Invest"},{"key":"2019041117351758200_R11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1210\/jcem-70-5-1347","article-title":"Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex.","volume":"70","author":"Baxter","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R12","first-page":"3","article-title":"Insulin-like growth factors and their binding proteins: biological actions.","volume":"16","author":"Jones","year":"1995","journal-title":"Endocr Rev"},{"key":"2019041117351758200_R13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/jcem-67-1-69","article-title":"Plasma insulin-like growth factor-I\/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.","volume":"67","author":"Barkan","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2265.1994.tb03787.x","article-title":"Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.","volume":"41","author":"Ho","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/jcem.86.1.7154","article-title":"The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.","volume":"86","author":"Peacey","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R16","first-page":"480","article-title":"Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency.","volume":"80","author":"Reutens","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0300-595X(84)80011-0","article-title":"Factors controlling blood concentration of somatomedin C.","volume":"13","author":"Clemmons","year":"1984","journal-title":"Clin Endocrinol Metab"},{"key":"2019041117351758200_R18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1056\/NEJM199004053221405","article-title":"Acromegaly.","volume":"322","author":"Melmed","year":"1990","journal-title":"N Engl J Med"},{"key":"2019041117351758200_R19","first-page":"1403","article-title":"Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors.","volume":"78","author":"Ho","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R20","first-page":"927","article-title":"Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.","volume":"80","author":"Grinspoon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2265.1995.tb02623.x","article-title":"IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly.","volume":"43","author":"De Herder","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R22","first-page":"1091","article-title":"Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.","volume":"86","author":"Arosio","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R23","doi-asserted-by":"crossref","first-page":"854","DOI":"10.7326\/0003-4819-116-10-854","article-title":"NIH conference. Insulin-like growth factors in health and disease.","volume":"116","author":"LeRoith","year":"1992","journal-title":"Ann Intern Med"},{"key":"2019041117351758200_R24","first-page":"80","article-title":"Nutritional regulation of the insulin-like growth factors.","volume":"15","author":"Thissen","year":"1994","journal-title":"Endocr Rev"},{"key":"2019041117351758200_R25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1009904031687","article-title":"Confusion in clinical laboratory GH and IGF-I reports.","volume":"2","author":"Melmed","year":"1999","journal-title":"Pituitary"},{"key":"2019041117351758200_R26","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1210\/jcem.87.8.8658","article-title":"Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.","volume":"87","author":"Dimaraki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R27","first-page":"1312","article-title":"Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women.","volume":"78","author":"Chapman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R28","first-page":"3808","article-title":"Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.","volume":"83","author":"Freda","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/jcem-70-3-771","article-title":"Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly.","volume":"70","author":"Hattori","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2265.1995.tb02651.x","article-title":"Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.","volume":"42","author":"Bates","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R31","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJM197911223012102","article-title":"Evaluation of acromegaly by radioimmunoassay of somatomedin-C.","volume":"301","author":"Clemmons","year":"1979","journal-title":"N Engl J Med"},{"key":"2019041117351758200_R32","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly.","volume":"86","author":"Bates","year":"1993","journal-title":"Q J Med"},{"key":"2019041117351758200_R33","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.","volume":"83","author":"Swearingen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3171\/jns.1986.64.5.0713","article-title":"Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas.","volume":"64","author":"Ebersold","year":"1986","journal-title":"J Neurosurg"},{"key":"2019041117351758200_R35","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","article-title":"Somatostatin analogs in acromegaly.","volume":"87","author":"Freda","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R36","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1210\/jcem.85.7.6699","article-title":"Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.","volume":"85","author":"Biermasz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8529(18)30210-X","article-title":"Treatment of acromegaly with dopamine agonists.","volume":"21","author":"Jaffe","year":"1992","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041117351758200_R38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003495-199447030-00004","article-title":"Acromegaly. Recognition and treatment.","volume":"47","author":"Jaffe","year":"1994","journal-title":"Drugs"},{"key":"2019041117351758200_R39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3171\/jns.1998.89.3.0353","article-title":"Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.","volume":"89","author":"Freda","year":"1998","journal-title":"J Neurosurg"},{"key":"2019041117351758200_R40","first-page":"1577","article-title":"Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas.","volume":"80","author":"Greenman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2265.1985.tb01116.x","article-title":"Long-term results of transsphenoidal pituitary microsurgery in 60 acromegalic patients.","volume":"23","author":"Roelfsema","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2265.1996.8370847.x","article-title":"Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.","volume":"45","author":"Sheaves","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R43","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1210\/jcem.84.10.6019","article-title":"Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas.","volume":"84","author":"Webb","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R44","first-page":"145","article-title":"Hypopituitarism following external radiotherapy for pituitary tumours in adults.","volume":"70","author":"Littley","year":"1989","journal-title":"Q J Med"},{"key":"2019041117351758200_R45","first-page":"2068","article-title":"Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.","volume":"85","author":"Powell","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R46","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3171\/jns.1988.68.6.0854","article-title":"Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients.","volume":"68","author":"Ross","year":"1988","journal-title":"J Neurosurg"},{"key":"2019041117351758200_R47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1464-5491.1991.tb01644.x","article-title":"Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide.","volume":"8","author":"James","year":"1991","journal-title":"Diabet Med"},{"key":"2019041117351758200_R48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1009980404404","article-title":"Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.","volume":"1","author":"Lancranjan","year":"1999","journal-title":"Pituitary"},{"key":"2019041117351758200_R49","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.","volume":"358","author":"Van Der Lely","year":"2001","journal-title":"Lancet"},{"key":"2019041117351758200_R50","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients.","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0889-8529(05)70062-1","article-title":"Medical therapy for acromegaly.","volume":"28","author":"Newman","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041117351758200_R52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jcem.82.2.3648","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly.","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1530\/eje.0.1390516","article-title":"Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?","volume":"139","author":"Cozzi","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2019041117351758200_R54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2265.1988.tb03695.x","article-title":"Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.","volume":"29","author":"Ferrari","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R55","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1365-2265.1997.2491023.x","article-title":"Cabergoline treatment of acromegaly: a preliminary dose finding study.","volume":"46","author":"Jackson","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R56","first-page":"2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.","volume":"81","author":"Biller","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"2019041117351758200_R58","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.","volume":"100","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"key":"2019041117351758200_R59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/edrv-9-4-417","article-title":"The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors.","volume":"9","author":"Lamberts","year":"1988","journal-title":"Endocr Rev"},{"key":"2019041117351758200_R60","first-page":"2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients\u2014a clinical research center study.","volume":"80","author":"Newman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2265.1998.00389.x","article-title":"Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.","volume":"48","author":"Davies","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003495-199753040-00009","article-title":"Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.","volume":"53","author":"Gillis","year":"1997","journal-title":"Drugs"},{"key":"2019041117351758200_R63","first-page":"3267","article-title":"Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.","volume":"80","author":"Stewart","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem.87.1.8153","article-title":"Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly.","volume":"87","author":"Caron","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/A:1009961116472","article-title":"Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.","volume":"2","author":"Chanson","year":"2000","journal-title":"Pituitary"},{"key":"2019041117351758200_R66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1530\/eje.0.1310020","article-title":"Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide.","volume":"131","author":"Marek","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"2019041117351758200_R67","first-page":"145","article-title":"Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.","volume":"79","author":"Morange","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R68","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.","volume":"87","author":"Bevan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/eje.0.1450137","article-title":"Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.","volume":"145","author":"Abe","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"2019041117351758200_R70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","article-title":"Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.","volume":"56","author":"Amato","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF03343849","article-title":"GH\/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.","volume":"24","author":"Attanasio","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"2019041117351758200_R72","first-page":"4099","article-title":"Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).","volume":"85","author":"Baldelli","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R73","first-page":"3132","article-title":"Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R74","first-page":"2779","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1210\/jcem.82.1.3572","article-title":"Sandostatin LAR in acromegalic patients: long-term treatment.","volume":"82","author":"Flogstad","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R76","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1507\/endocrj.45.269","article-title":"Preoperative treatment of growth hormone-producing pituitary adenoma with continuous subcutaneous infusion of octreotide.","volume":"45","author":"Tamura","year":"1998","journal-title":"Endocr J"},{"key":"2019041117351758200_R77","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/0003-4819-117-9-711","article-title":"Octreotide treatment of acromegaly. A randomized, multicenter study.","volume":"117","author":"Ezzat","year":"1992","journal-title":"Ann Intern Med"},{"key":"2019041117351758200_R78","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2362.1997.1190659.x","article-title":"Clinical results of long-term slow-release lanreotide treatment of acromegaly.","volume":"27","author":"Giusti","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"2019041117351758200_R79","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-121-7-199410010-00002","article-title":"Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.","volume":"121","author":"Grunstein","year":"1994","journal-title":"Ann Intern Med"},{"key":"2019041117351758200_R80","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","article-title":"Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.","volume":"75","author":"Giustina","year":"1995","journal-title":"Am J Cardiol"},{"key":"2019041117351758200_R81","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/eje.0.1460701","article-title":"New somatostatin analogs: will they fulfill old promises?","volume":"146","author":"Lamberts","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2019041117351758200_R82","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1210\/jc.2002-011841","article-title":"Guidelines for acromegaly management.","volume":"87","author":"Melmed","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R83","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"2019041117351758200_R84","first-page":"2989","article-title":"Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.","volume":"86","author":"Trainer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","article-title":"Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.","volume":"56","author":"Parkinson","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R86","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.","volume":"87","author":"Sesmilo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R87","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1210\/jcem.86.2.7206","article-title":"Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.","volume":"86","author":"Van Der Lely","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00006123-199702000-00001","article-title":"Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.","volume":"40","author":"Ciric","year":"1997","journal-title":"Neurosurgery"},{"key":"2019041117351758200_R89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/194589240101500411","article-title":"Endoscopic transnasal pituitary surgery: report on 180 cases.","volume":"15","author":"Nasseri","year":"2001","journal-title":"Am J Rhinol"},{"key":"2019041117351758200_R90","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2265.1998.00581.x","article-title":"The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.","volume":"49","author":"Lissett","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041117351758200_R91","first-page":"3034","article-title":"Octreotide as primary therapy for acromegaly.","volume":"83","author":"Newman","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117351758200_R92","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1210\/jcem.85.10.6870","article-title":"Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.","volume":"85","author":"Barrande","year":"2000","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/10\/4759\/10404513\/jcem4759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T02:04:31Z","timestamp":1555034671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/88\/10\/4759\/2845772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2003-030518","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}